A detailed history of Marshall Wace, LLP transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 14,031 shares of LIFE stock, worth $26,097. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,031
Holding current value
$26,097
% of portfolio
0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.51 - $2.24 $21,186 - $31,429
14,031 New
14,031 $26,000
Q1 2024

May 15, 2024

BUY
$1.42 - $2.02 $225,238 - $320,410
158,619 New
158,619 $309,000
Q1 2023

May 15, 2023

SELL
$1.88 - $2.5 $243,176 - $323,372
-129,349 Reduced 92.2%
10,947 $22,000
Q4 2022

Feb 14, 2023

SELL
$2.02 - $2.49 $71,940 - $88,678
-35,614 Reduced 20.25%
140,296 $307,000
Q3 2022

Nov 14, 2022

BUY
$2.79 - $4.15 $46,043 - $68,487
16,503 Added 10.35%
175,910 $527,000
Q2 2022

Aug 15, 2022

SELL
$2.63 - $5.61 $114,668 - $244,596
-43,600 Reduced 21.48%
159,407 $450,000
Q1 2022

May 16, 2022

SELL
$4.75 - $7.54 $225,097 - $357,313
-47,389 Reduced 18.93%
203,007 $1.09 Million
Q4 2021

Feb 14, 2022

BUY
$7.29 - $9.5 $1.51 Million - $1.97 Million
207,390 Added 482.24%
250,396 $1.87 Million
Q3 2021

Nov 15, 2021

BUY
$4.22 - $12.48 $181,485 - $536,714
43,006 New
43,006 $390,000

Others Institutions Holding LIFE

About aTYR PHARMA INC


  • Ticker LIFE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,625,000
  • Market Cap $53.2M
  • Description
  • aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...
More about LIFE
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.